CD274 and triple-negative breast carcinoma: Seventy-four percent of panelists did not agree to give women having either stage II or also stage III triple-negative breast cancer (who have not been treated by neoadjuvant but receiving adjuvant chemotherapy) anti-PD1/PDL1 therapy.